⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Lantheus Holdings, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Lantheus Holdings, Inc.
↗Bedford, Massachusetts, USA
Lantheus is a leading radiopharmaceutical-focused company committed to enabling clinicians to 'Find, Fight and Follow' disease to deliver better patient outcomes. The company develops, manufactures, and commercializes innovative radiodiagnostics and radiotherapeutics, with a strategic focus on PET radiodiagnostics in oncology and neurology.
Headquartered in Bedford, Massachusetts, Lantheus has a 70-year history in medical imaging. The company is currently undergoing a strategic transition to simplify its operating model, which includes divesting its legacy SPECT business and prioritizing investment in high-growth PET radiodiagnostics and late-stage pipeline assets.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$1.4B-$1.45B
Founded:1956
Ownership:public
Status:operating
STOCK
Exchange:NASDAQ
Ticker:LNTH
Market Cap:$5.05B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Radiopharmaceuticals, PET Radiodiagnostics
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, EXINI Diagnostics AB
Key Partnerships:Bayer, Novartis, Regeneron, GE Healthcare, Siemens Healthineers
COMPETITION
Position:Leader
LEADERSHIP
Key Executives:
Brian Markison - CEO
LINKS
Website:lantheus.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Lantheus Holdings, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.